Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 2, 2026, 5:47 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–10 of 10 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Poziotinib Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Effect of Multiple Doses of Itraconazole, Phenytoin, and Paroxetine on the Single-Dose Pharmacokinetics of Poziotinib in Healthy Adult Participants

NCT04981704
View directory record Official record
Conditions
Healthy
Interventions
Poziotinib, Itraconazole, Phenytoin, Paroxetine
Drug
Lead sponsor
Spectrum Pharmaceuticals, Inc
Industry
Eligibility
18 Years to 55 Years
Enrollment
74 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Sep 4, 2021 · Synced Sep 2, 2026, 5:47 PM EDT
Terminated Phase 2 Interventional Results available

Phase 2 Study of Poziotinib in Participants With NSCLC Having EGFR or HER2 Exon 20 Insertion Mutation

NCT03318939
View directory record Official record
Conditions
NSCLC
Interventions
Poziotinib
Drug
Lead sponsor
Spectrum Pharmaceuticals, Inc
Industry
Eligibility
18 Years and older
Enrollment
648 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
43
States / cities
Phoenix, Arizona • Arcadia, California • Duarte, California + 37 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2026 · Synced Sep 2, 2026, 5:47 PM EDT
Suspended Phase 3 Interventional

A Study of Poziotinib in Previously Treated Participants With Locally Advanced or Metastatic NSCLC Harboring HER2 Exon 20 Mutations

NCT05378763
View directory record Official record
Conditions
NSCLC
Interventions
Poziotinib, Docetaxel
Drug
Lead sponsor
Spectrum Pharmaceuticals, Inc
Industry
Eligibility
18 Years and older
Enrollment
268 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
1
States / cities
Winter Haven, Florida
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Sep 2, 2026, 5:47 PM EDT
Terminated Phase 1 Interventional

A Mass Balance and Pharmacokinetics Study of 14C-Labeled Poziotinib in Cancer Patients Suitable for Treatment With Poziotinib

NCT03804515
View directory record Official record
Conditions
Solid Tumor
Interventions
14C-labeled poziotinib
Drug
Lead sponsor
Spectrum Pharmaceuticals, Inc
Industry
Eligibility
18 Years to 90 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 14, 2021 · Synced Sep 2, 2026, 5:47 PM EDT
Terminated Phase 2 Interventional

Poziotinib in EGFR Exon 20 Mutant Advanced NSCLC

NCT03066206
View directory record Official record
Conditions
EGFR Exon 20 Mutation, ERBB2 Gene Mutation, Recurrent Lung Non-Small Cell Carcinoma, Stage IV Non-Small Cell Lung Cancer AJCC v7
Interventions
Poziotinib
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 19, 2026 · Synced Sep 2, 2026, 5:47 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study of the Absorption, Metabolism, and Excretion Following a Single Dose of [14C]-Poziotinib in Healthy Male Subjects

NCT04436562
View directory record Official record
Conditions
Healthy
Interventions
[14C]-Poziotinib
Drug
Lead sponsor
Spectrum Pharmaceuticals, Inc
Industry
Eligibility
18 Years to 65 Years · Male only
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jan 14, 2021 · Synced Sep 2, 2026, 5:47 PM EDT
Terminated Phase 1 Interventional

A Study of Poziotinib in Combination With T-DM1 in HER2-Positive Breast Cancer

NCT03429101
View directory record Official record
Conditions
Breast Cancer
Interventions
Poziotinib, T-DM1
Drug
Lead sponsor
Spectrum Pharmaceuticals, Inc
Industry
Eligibility
18 Years to 90 Years · Female only
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
2
States / cities
Anaheim, California • Glendale, California
Source: ClinicalTrials.gov public record
Updated Jan 14, 2021 · Synced Sep 2, 2026, 5:47 PM EDT
Terminated Phase 2 Interventional Results available

A Study to Allow Continued Dosing and/or Follow-up of Patients Who Have Had Previous Exposure to Poziotinib

NCT03744715
View directory record Official record
Conditions
NSCLC, Breast Cancer
Interventions
Poziotinib
Drug
Lead sponsor
Spectrum Pharmaceuticals, Inc
Industry
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
5
States / cities
Long Beach, California • Hattiesburg, Mississippi • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 27, 2026 · Synced Sep 2, 2026, 5:47 PM EDT
Completed Phase 2 Interventional Results available

Study of Poziotinib in Participants With HER2-Positive Metastatic Breast Cancer

NCT02659514
View directory record Official record
Conditions
Breast Cancer
Interventions
Poziotinib
Drug
Lead sponsor
Spectrum Pharmaceuticals, Inc
Industry
Eligibility
18 Years to 90 Years
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
35
States / cities
Huntsville, Alabama • Anaheim, California • Greenbrae, California + 31 more
Source: ClinicalTrials.gov public record
Updated Mar 10, 2022 · Synced Sep 2, 2026, 5:47 PM EDT
Terminated Phase 2 Interventional Results available

A Study of Poziotinib in Patients With Epidermal Growth Factor Receptor (EGFR) or Human Epidermal Growth Factor Receptor 2 (HER2) Activating Mutations in Advanced Malignancies

NCT04172597
View directory record Official record
Conditions
Breast Cancer, Colorectal Cancer, Solid Tumor, Glioblastome Multiforme
Interventions
Poziotinib Hydrochloride, Loperamide
Drug
Lead sponsor
Spectrum Pharmaceuticals, Inc
Industry
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Long Beach, California
Source: ClinicalTrials.gov public record
Updated Mar 12, 2024 · Synced Sep 2, 2026, 5:47 PM EDT